According to studies, pembrolizumab monotherapy is a suitable first-line treatment for patients with PD-L1-positive recurrent or metastatic HNSCC and pembrolizumab combined with chemotherapy is a suitable first-line treatment for recurrent or metastatic HNSCC patients8. Here, CD274 is linked to head and neck squamous cell carcinoma.